Correction: Discovery of Entrectinib: A New 3-Aminoindazole as a Potent Anaplastic Lymphoma Kinase (ALK), c-ros Oncogene 1 Kinase (ROS1), and Pan-Tropomyosin Receptor Kinases (Pan-TRKs) inhibitor (Journal of Medicinal Chemistry (2016) 59: 7 (3392-3408) DOI: 10.1021/acs.jmedchem.6b00064)
Clicks: 235
ID: 92814
2019
Article Quality & Performance Metrics
Overall Quality
Not rated
Combines reader engagement with the AI quality analysis. This
article has not been analysed, so there is no overall score —
reader engagement is measured and shown alongside.
Reader Engagement
Steady Performance
30.0
/100
235 views
36 readers
AI Quality Assessment
Not analyzed
Readership in this journal
SteadyRanked #37 of 122 articles by views in Journal of medicinal chemistry
Most read
Least read
Bar heights use a square-root scale. Only the 120 most-read articles are drawn; the journal has 122 in total.
Mint this article as an NFT
Not yet mintedCreate a permanent, verifiable on-chain record of this article on the Scimatic Network. The NFT is held in your Journament account, and you can withdraw it to your own wallet at any time.
5
SUSD
one-off · no wallet required
Abstract
Abstract is not available for this article.
Login to Search Abstract
| Reference Key |
menichincheri2019correctionjournal
Use this key to autocite in the manuscript while using
SciMatic Manuscript Manager or Thesis Manager
|
|---|---|
| Authors | Menichincheri, M. |
| Journal | Journal of medicinal chemistry |
| Year | 2019 |
| DOI |
10.1021/acs.jmedchem.9b01259
|
| URL | |
| Keywords | Keywords not found |
Citations
No citations found. To add a citation, contact the admin at info@scimatic.org
Comments
No comments yet. Be the first to comment on this article.